This week's biotech landscape witnessed key FDA approvals, rejections, NDA resubmissions, merger terminations, trial discontinuations, and clinical trial data readouts across therapeutic areas such as Turner Syndrome, Late-Line Colorectal Cancer, Obesity, and Type 1 Diabetes. Let us unpack the key developments and milestones in the biotech space this week. FDA and EU Approvals & Rejections GSK's Lynavoy Wins FDA Approval for Cholestatic Pruritus in PBC GSK plc (GSK), secured for Lynavoy, the first U.S. tre ...

分组1 - Monte Rosa Therapeutics reported a quarterly loss of $0.55 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.47, and a significant decline from earnings of $0.23 per share a year ago, resulting in an earnings surprise of -17.02% [1] - The company posted revenues of $2.78 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 72.9%, and a sharp decline from year-ago revenues of $60.65 million [2] - The stock has added about 4.3% since the beginning of the year, contrasting with the S&P 500's decline of 2.1% [3] 分组2 - The earnings outlook for Monte Rosa Therapeutics is uncertain, with current consensus EPS estimates of -$0.29 on $20.86 million in revenues for the coming quarter and -$1.03 on $96.21 million in revenues for the current fiscal year [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is currently in the bottom 43% of over 250 Zacks industries, indicating potential challenges for the stock's performance [8] - The estimate revisions trend for Monte Rosa Therapeutics was unfavorable ahead of the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, suggesting expected underperformance in the near future [6]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40522 Monte Rosa Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) Delaware 84-3766197 (State or other jurisd ...

Financial Performance - Monte Rosa reported a net loss of $46.1 million for Q4 2025, compared to a net loss of $13.4 million in Q4 2024, and a net loss of $38.6 million for the full year 2025, down from $72.7 million in 2024[18]. - Total operating expenses for the year ended December 31, 2025, were $177.9 million, compared to $156.7 million in 2024, reflecting an increase in research and development costs[29]. - The net loss for the year ended December 31, 2025, was $38.6 million, an improvement from a net loss of $72.7 million in 2024[29]. Revenue and Collaboration - Collaboration revenue for Q4 2025 was $2.8 million, significantly lower than $60.6 million in Q4 2024, while total collaboration revenue for 2025 was $123.7 million, up from $75.6 million in 2024[15]. - Collaboration revenue for the year ended December 31, 2025, was $123.7 million, an increase from $75.6 million in 2024[29]. - The company has a collaboration agreement with Novartis for MRT-6160, with potential milestone payments up to $2.1 billion and shared profits from U.S. commercialization[14]. Expenses - Research and Development (R&D) expenses increased to $42.0 million in Q4 2025 from $38.9 million in Q4 2024, with total R&D expenses for 2025 reaching $141.5 million, compared to $121.6 million in 2024[16]. - General and Administrative (G&A) expenses rose to $10.5 million in Q4 2025 from $8.8 million in Q4 2024, with total G&A expenses for 2025 at $36.4 million, compared to $35.2 million in 2024[17]. Cash and Funding - As of December 31, 2025, the company's cash, cash equivalents, restricted cash, and marketable securities totaled $382.1 million, a decrease of $14.1 million from $396.2 million as of September 30, 2025[19]. - The company closed a public equity offering in January 2026, generating approximately $345.0 million in gross proceeds, with net proceeds expected to be around $323.8 million after expenses[20]. - The company anticipates that its cash and cash equivalents, along with proceeds from the 2026 offering, will be sufficient to fund operations and capital expenditures into 2029[21]. - Monte Rosa raised $345 million through an upsized public offering, strengthening its balance sheet to support operations into 2029[2]. Clinical Development - MRT-8102 demonstrated a 85% reduction in CRP levels after four weeks of administration in subjects with elevated CVD risk, with 94% of participants achieving CRP levels below 2 mg/L[4]. - The company plans to initiate multiple Phase 2 studies of MRT-8102, including in patients with Stage 3/4 chronic kidney disease in H2 2026, gout flare patients in Q4 2026/Q1 2027, and hidradenitis suppurativa patients in H1 2027[12]. - Anticipated readout of the GFORCE-1 study for MRT-8102 in subjects with elevated CVD risk is expected in H2 2026[13]. - The company plans to initiate the MODeFIRe-1 Phase 2 study of MRT-2359 in combination with apalutamide in mCRPC in Q3 2026[22]. - An IND application for a cyclin E1-directed MGD is expected to be submitted in 2026[22]. - MRT-2359 showed a 100% PSA response rate in mCRPC patients with AR mutations, with a 67% overall RECIST disease control rate across 15 evaluable patients[7]. Pipeline Development - The company has developed a leading pipeline of first-in-class and only-in-class molecular glue degraders (MGDs) across various therapeutic areas, with three programs currently in the clinic[23]. - The total assets as of December 31, 2025, were $448.7 million, compared to $438.7 million as of December 31, 2024[27].

Core Insights - Monte Rosa Therapeutics reported positive interim Phase 1 data for its NEK7-directed MGD MRT-8102, showing significant reductions in high-sensitivity C-reactive protein (hsCRP) in subjects at elevated cardiovascular disease (CVD) risk, with further data expected from the expanded GFORCE-1 trial in H2 2026 [1][2][6] - The company plans to initiate multiple Phase 2 studies for MRT-8102 targeting various conditions, including elevated CVD risk, gout flares, and hidradenitis suppurativa, with timelines extending into 2027 [1][2][22] - Monte Rosa also presented promising data for MRT-2359 in combination with enzalutamide, achieving a 100% PSA response rate in metastatic castration-resistant prostate cancer (mCRPC) patients, with a Phase 2 study planned for Q3 2026 [1][12] - The company secured $345 million in follow-on financing, enhancing its financial position to support operations through 2029 and multiple anticipated clinical developments [1][13][20] Clinical Developments - MRT-8102 demonstrated an 85% reduction in CRP levels after four weeks of administration, with 94% of participants achieving CRP levels below 2 mg/L, indicating a strong potential for cardiovascular applications [6] - The unblinded safety data from the Phase 1 study showed no serious adverse events and a lower rate of treatment-emergent adverse events (22% for MRT-8102 vs. 32% for placebo), supporting its favorable safety profile [6] - Monte Rosa is advancing MRT-6160, a VAV1-directed MGD, towards Phase 2 studies in collaboration with Novartis, with a focus on immune-mediated diseases [1][5][7] Financial Performance - Collaboration revenue for Q4 2025 was $2.8 million, a decrease from $60.6 million in Q4 2024, while total collaboration revenue for the year was $123.7 million, up from $75.6 million in 2024 [14] - Research and development expenses increased to $42.0 million in Q4 2025 from $38.9 million in Q4 2024, reflecting heightened investment in the MRT-8102 program [15] - The net loss for Q4 2025 was $46.1 million, compared to $13.4 million in Q4 2024, with a total net loss of $38.6 million for the year, down from $72.7 million in 2024 [17] Future Outlook - Monte Rosa plans to initiate several Phase 2 studies for MRT-8102, including GFORCE-2 for patients with chronic kidney disease in H2 2026, GFORCE-3 for gout flares in Q4 2026/Q1 2027, and GFORCE-4 for hidradenitis suppurativa in H1 2027 [22] - The company expects to submit an IND application for a second-generation NEK7-directed MGD in 2026 and anticipates Novartis to initiate multiple Phase 2 studies of MRT-6160 in 2026 [22] - Monte Rosa is also advancing its cyclin E1 and CDK2-directed MGD programs for solid tumors, with an IND application expected in 2026 [9][22]

Monte Rosa Therapeutics (GLUE) advanced in premarket trading on Monday as the company entered into a supply agreement with Johnson & Johnson (JNJ) to evaluate its MRT-2359 in combination with apalutamide for treating metastatic castration-resistant prostate cancer ...

MRT-2359 is an investigational, orally bioavailable, GSPT1-directed molecular glue degrader that has shown compelling clinical activity in combination with androgen receptor (AR) inhibition in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients with AR mutations in an ongoing Phase 1/2 clinical study Monte Rosa plans to initiate a new, signal-confirming Phase 2 study of MRT-2359 in combination with apalutamide targeting AR mutant patients in Q3 2026 BOSTON, March 16, 2026 (G ...

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Monte Rosa Therapeutics due to lower revenues, with a focus on how actual results will compare to estimates [1] Earnings Expectations - Monte Rosa Therapeutics is expected to report a quarterly loss of $0.47 per share, reflecting a year-over-year change of -304.4% [3] - Revenues are projected to be $10.26 million, down 83.1% from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised 6.52% higher in the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Monte Rosa is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +2.13% [11] Earnings Surprise Potential - A positive Earnings ESP reading suggests a likely earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [9] - Monte Rosa has a Zacks Rank of 3, indicating a potential to beat the consensus EPS estimate [11] Historical Performance - In the last reported quarter, Monte Rosa was expected to post a loss of $0.39 per share but actually reported a loss of -$0.33, resulting in a surprise of +15.38% [12] - The company has beaten consensus EPS estimates in the last four quarters [13] Industry Context - Kyntra Bio, another company in the biomedical and genetics industry, is expected to report a loss of $3.89 per share, indicating a year-over-year change of -94.5% [17] - Kyntra Bio's revenues are expected to be $1.6 million, down 49% from the previous year, with an Earnings ESP of +24.07% [18][19]

Summary of Monte Rosa Therapeutics FY Conference Call Company Overview - **Company**: Monte Rosa Therapeutics (NasdaqGS:GLUE) - **Industry**: Biotechnology, focusing on innovative drug development using molecular glue technology Key Highlights Platform Technology - Monte Rosa's platform technology utilizes **molecular glue degraders**, which can target previously undruggable proteins without needing a binding site, unlike heterobifunctional degraders that require a binding component [3][4] - This technology allows for the degradation of disease-causing proteins by reshaping E3 ligases, specifically targeting proteins involved in inflammatory and oncological diseases [3][4] Pipeline Progress - **MRT-6160**: A VAV1 degrader licensed to Novartis, with Monte Rosa retaining 30% of P&L shares in the U.S. The next milestone includes initiating multiple Phase 2 programs in inflammatory and immune indications [5][6] - **MRT-8102**: A NEK7 degrader targeting the NLRP3 inflammasome, currently in clinical trials. Early data showed significant CRP modulation in high cardiovascular risk subjects, with a 85% reduction in CRP levels by week four [7][10] - The **GFORCE-1 study** is testing multiple dose levels of MRT-8102 in subjects with high cardiovascular risk, with results expected in the second half of the year [8][19] Mechanism of Action - NEK7 plays a crucial role in the assembly of the NLRP3 inflammasome, and its degradation leads to a sustained pharmacodynamic effect, differentiating it from other treatments that may cause rebound effects [9][10] - The CRP suppression observed is comparable to IL-6 antibodies, achieved with lower doses, indicating a favorable safety profile [10][11] Future Studies - **GFORCE-2 study**: Planned to further explore the effects of MRT-8102 with longer administration and to gather more safety data before larger Phase 3 trials [21][23] - The company is also exploring other indications for NEK7 targeting, including chronic gout and pericarditis, which are heavily dependent on the NLRP3 pathway [31][33] Oncology Developments - **MRT-2359**: In a Phase 1 trial for metastatic castration-resistant prostate cancer, a 100% PSA response rate was observed in patients with AR mutations, indicating strong potential for further development [35][36] - A signal confirming study is planned for Q3 of this year, focusing on AR mutant castration-resistant prostate cancer [37][38] Collaborations and Future Catalysts - Collaboration with Novartis on the VAV1 program is ongoing, with multiple Phase 2 trials expected to start this year [42] - Major upcoming catalysts include data updates from the GFORCE-1 study and the initiation of the signal confirming study for MRT-2359 [43] Additional Insights - The company is optimistic about the addressable population for ASCVD, estimated at over 10 million in the U.S., and is considering various other indications for its therapies [31][32] - Monte Rosa aims to differentiate its products by targeting specific inflammatory pathways without affecting other necessary immune responses, potentially reducing safety liabilities seen in other treatments [25][26] This summary encapsulates the key points discussed during the conference call, highlighting Monte Rosa's innovative approach to drug development and its strategic focus on addressing unmet medical needs in both inflammatory and oncological diseases.

Monte Rosa Therapeutics FY Conference Summary Company Overview - **Company**: Monte Rosa Therapeutics (NasdaqGS:GLUE) - **Industry**: Biotechnology, specifically focused on targeted protein degradation - **Established**: 7 years ago - **Core Technology**: Molecular glue degraders aimed at removing proteins in cells to develop medicines [2][3] Key Points and Arguments Clinical Programs and Data - **Clinical Trials**: Monte Rosa has three programs in the clinic, all producing positive clinical data. Plans to initiate at least one, and in some cases multiple, Phase 2 trials within the year [3][4] - **Collaboration Revenue**: Over $300 million in collaboration revenue generated in the last year, contributing to a strong balance sheet [4] - **NEK7 Degrader (MRT-8102)**: Focused on the NLRP3 inflammasome pathway, with significant data showing an 85% reduction in CRP levels in obese individuals with elevated CRP [8][9] - **CRP Normalization**: 94% of individuals in the study normalized their CRP levels, indicating strong efficacy compared to competitors [9][10] - **Safety Profile**: No toxicity concerns reported in Phase 1 studies, allowing for extended dosing in Phase 2 trials [11][28] Future Trials and Indications - **GFORCE-1 Study**: Expansion of the original Phase 1 trial into a Phase 2a study with additional dose levels to better understand the dose-response relationship [12][34] - **Oncology Focus**: Lead oncology project targets GSPT1, showing a 100% response rate in patients with androgen receptor mutations [14][45] - **Future Indications**: Plans to explore additional indications such as gout and hidradenitis, with a focus on self-development for certain conditions [35][39] Strategic Considerations - **Partnerships**: While ASCVD remains a top priority, the company is open to strategic partnerships for larger indications if necessary [41][42] - **Molecular Space**: Development of a second molecule to diversify the portfolio and enhance strategic options for future pricing and partnerships [42] Additional Important Insights - **VAV1 Target**: Selected for its potential in autoimmune diseases, with indications not yet disclosed but aligned with Novartis [52][53] - **Market Position**: Monte Rosa positions itself as a leader in targeted protein degradation, with a strong emphasis on innovative approaches to drug development [3][4] This summary encapsulates the key points discussed during the conference, highlighting Monte Rosa Therapeutics' strategic direction, clinical advancements, and future opportunities in the biotechnology sector.